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Objectives: To evaluate the effectiveness of an adjuvant therapy (CoQ10 in its water-
soluble form and vitamin A) in supporting voice rehabilitation in a large group of patients 
with muscle tension dysphonia (MTD).
Study Design: Twelve-week, double-blind, randomized, controlled, three-period cross-
over pilot study. The primary endpoint was the change in the Dysphonia Severity Index 
(DSI) over the 12-week study period. Secondary endpoints were the changes in the 
subcomponents of DSI, including MPT, F0-high, I-low, and jitter. Exploratory endpoints 
were the changes in the Shimmer and in Voice Handicap Index (VHI).
Methods: Patients were randomly assigned in a 1:1 ratio to two counter-balanced 
arms. Group A (ADJ-PLA) patients were administered QTer 300 mg and Vit A acetate 
500.000 Ul/g 1 mg twice daily for a 4-week intervention period, followed by a 4-week 
period of wash-out, and then were submitted to a last 4-week period of placebo. Patients 
in Group B (PLB-ADJ) were given the treatment period in reverse order. Both groups 
received a 45-min voice therapy in a group format once a day for 4 weeks during the first 
and the second active periods. The therapy was held during the wash-out period.
Results: The analysis of main time effect indicated a trend toward recovery of vocal function 
regardless of group assignment. A significant time by group effect was found on DSI [F = 
3.4 (2.5, 80.5), p = 0.03], F0-high [F = 4.5 (2.6, 82.9), p = 0.008] and Shimmer [F = 3.6 (1.5, 
46.9), p = 0.048], under CoQ10 and Vit A treatment, with a small effect size. There was no 
significant time by group effect on the other study measures, namely MPT, I-low, VHI.
Conclusions: A trend toward recovery of vocal function was observed in all the patients, 
likely due to voice rehabilitation. The improvement of DSI was greater under CoQ10 and 
Vitamin treatment, indicating a more pronounced improvement of vocal quality under 
adjuvant therapy. The study protocol was reviewed and approved by the Ethics Committee 
of Policlinico Umberto I Hospital, Rome, Italy Rif. 3069/13.02.2014.
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INTRODUCTION
Functional disorders of voice are frequent in the general population 
and particularly common among professional voice users. In a 
study on 2019 patients with dysphonia of different etiologies, 
functional dysphonia was found in 17% of subjects (Mozzanica 
et al., 2016), whereas in a Belgic treatment-seeking population, 
the functional voice disorders were diagnosed in 30% of patients. 
(Martins et al., 2016). Undoubtedly, the heavy voice demand 
associated to some professions increases the risk for voice 
disorders. For example, the reported prevalence of functional 
dysphonia is of 46% in call center operators and ranges from 20% 
to 80% in teachers. Occupational voice disorders can involve the 
social and the economic status of patients and must be considered 
an important health issue (Hazlett et al., 2011; Niebudek-Bogusz 
and Śliwińska-Kowalska, 2013).
Functional disorders of voice are defined as alterations of 
voice quality in absence of identifiable lesions, and there is a 
general agreement among researchers on their etiology, mainly 
attributable to an improper voicing behavior. Recently, the main 
cause of vocal dysfunction has been identified in the increased 
muscle tension or effort: similar voice pathologies, previously 
labeled as vocal hyperfunction, hyperkinetic dysphonia, tension-
fatigue syndrome, muscle misuse, functional, nonorganic 
dysphonia, have been grouped together in the broader definition 
of primary muscle tension dysphonia (MTD) (Roy et al., 2019). 
Voice therapy, aimed both to restore a proper vocal behavior 
and to treat specific alterations in voice-producing mechanisms, 
is the first-line treatment of functional voice disorders, even if 
poor evidence supports its effectiveness (Ruotsalainen et al., 
2007). Due to the muscular effort that characterizes the MTD, 
it is reasonable to assume the usefulness of an adjuvant therapy 
to support muscle fatigue. Several studies support the efficacy 
of the ubiquinol, particularly in the reduced and active form 
of coenzyme Q10 (CoQ10), in improving the performance 
and decreasing the fatigue in subjects undergoing different 
workloads (Orlando et al., 2018), as well as improving the 
impaired myocardial bioenergetics in patients with heart failure 
and preserved left ventricular ejection fraction (Pierce et al., 
2018). Ubiquinol is a lipid-soluble molecule composed of a 
redox-active quinone ring and a hydrophobic tail. The high 
concentration of this molecule in the mitochondria confirms 
its role in the mitochondrial respiratory chain where it acts as a 
mobile electron transporter. In a recent study on cultured cells 
(Bergamini et al., 2012), the water-soluble formulation of CoQ10 
(Qter) showed to be more efficient than the native CoQ10 in 
increasing mitochondrial ubiquinone levels, leading to a general 
improvement of bioenergetics parameters, such as oxygen 
consumption, ATP content, mitochondrial potential, and protein 
synthesis. To the best of our knowledge, there is no study in 
literature about the efficacy of CoQ10 alone on vocal pathologies. 
With regard to vitamin supplementation, retinoic acid (vitamin 
A) has been widely used for decades by the otologists to treat 
laryngeal leucoplakia (Issing et al., 1996) and for the maintenance 
of the normal structure and texture of the respiratory epithelium. 
Furthermore, vitamin A was found in the vocal fold stellate 
cells, which are involved in the metabolism of the extracellular 
matrix of the lamina propria of the vocal fold, whose viscoelastic 
properties play an essential role in the vocal fold vibration (Sato 
et al., 2003; Sato et al., 2004; Sato et al., 2010). Therefore, it can 
be postulated that the combination of CoQ10 and Vitamin A is 
useful to support the therapy of functional pathologies of voice. 
This has been already hypothesized in several reports, which are 
all limited by the observational design and the lack of the control 
arm. Of these, only one appears in international databases 
(Sensini et al., 2011).
The aim of our study was, therefore, to evaluate the effectiveness 
of CoQ10 in its water-soluble form (Qter) and vitamin A in 
supporting voice therapy in a large group of patients with MTD, 
in a 12-week, double-blind, randomized, controlled, three-
period cross-over pilot study. The finding of potential benefits 
of adjuvant therapy could help to shorten and make speech 
therapy more effective, with a consequent reduction in health 
expenditure and working hours lost by voice professionals.
The primary endpoint was the change in the Dysphonia 
Severity Index (DSI) (Wuyts et al., 2000) over the 12-week 
study period. Secondary endpoints were the changes in the 
subcomponents of DSI, including MPT, F0-high, I-low, and jitter. 
Exploratory endpoints were the changes in the Shimmer and in 
Voice Handicap Index (VHI).
MATERIALS AND METHODS
Participants
Fifty patients referred to the Operative Unit of Phoniatrics of 
the Azienda Policlinico Umberto I Hospital of Rome for MTD 
dysphonia were asked to participate in the trial in combination 
with voice rehabilitation. Inclusion criteria were: 18 years or older 
and 70 years or younger and a definite diagnosis of MTD without 
secondary mucosal changes (e.g., epithelial thickening such as 
nodules or polyps). Exclusion criteria were diagnosis of organic, 
post-surgical or neurological dysphonia; concomitant diseases 
(endocrine, metabolic, neurologic disorders) that could be 
associated with dysphonia; laryngopharyngeal reflux; psychiatric 
disorders or other conditions that could interfere with the study 
design. Concurrent diseases and psychiatric disorders were 
verified using a dedicated checklist where detailed questions were 
asked. The presence of reflux signs or organic lesions was verified 
by laryngostrobosocopy. In particular, all patients with a Reflux 
Finding Score ≥ 2 were excluded (Belafsky et al., 2001). The 
presence of vocal tremor or other signs of neurological damage 
was excluded by spectrography. All subjects with alterations in 
the thyroid hormone metabolism, even if treated, were excluded.
The study protocol was approved by the Ethical Committee 
of Policlinico Umberto I, Rome, Italy, and was conducted in 
accordance with the International Conference on Harmonization 
Guidelines for Good Clinical Practice and the declaration of 
Helsinki. Each patient provided written informed consent before 
any study-related procedure.
Study Design
Patients who met the eligibility criteria underwent study 
assessments and were randomly assigned in a 1:1 ratio to two 
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counter-balanced arms (group A–group B) by computer-
generated random numbers. An operator not involved in study 
measurements performed the randomization procedure. Both 
patients and operators were blinded to assignments.
Group A (ADJ-PLA) patients were administered QTer 300 mg 
(equal to CoQ10 30 mg) and Vit A acetate 500,000 Ul/g 1 mg 
twice daily for a 4-week intervention period, followed by a 4-week 
period of wash-out, and then were submitted to a last 4-week 
period of placebo (inert tablets resembling the active medication). 
Patients in group B (PLB-ADJ) were given the treatment period 
in reverse order. Both groups received an intensive 45-min voice 
therapy in a group format (six participants) once a day from 
Monday to Friday for 4 weeks during the first and the second 
active periods. The therapy was held during the wash-out period 
(Figure 1).
Patients were encouraged to contact the responsible study 
person (RG) in case of any adverse event (defined as any 
untoward medical occurrence regardless of its causal relationship 
to the study intervention) that could occur during the 12-week 
study period.
Study assessments were conducted at randomization (T0), after 
the first 4-week period (T1), at the end of the wash-out period 
(T2), and finally at the end of the 12-week study period (T3).
Study Assessments
All patients underwent a comprehensive voice examination 
as follows:
• Dysphonia Severity Index (DSI): DSI is a validated multiparametric 
indicator for the assessment of the severity of dysphonia and a 
suitable method for dysphonia quantification (Hakkesteegt 
et al., 2008; Hakkesteegt et al., 2010; Van Lierde et al., 2010). It 
is calculated by means of a weighted combination of the highest 
possible frequency (F0high), the lowest intensity (Ilow), Maximum 
Phonation Time (MPT), and jitter% (an acoustic analysis of 
relative pitch disturbance), using the following formula: 0.13 
MPT + 0.0053 Fhigh - 0.26 Ilow - 1.18 jitter (%) + 12.4. The DSI 
for perceptually normal voices equals +5 (or 100%) and for 
severely dysphonic voices equals -5 (or 0%). The more negative 
the patient’s index, the worse is the voice quality.
• Shimmer%: acoustic analysis of relative amplitude disturbance.
• MPT: maximum phonation time is the longest period during 
which a patient, after taking a deep breath, can sustain 
phonation of a vowel sound. In dysphonic patients, it is used 
also to objectively assess the progresses after voice therapy 
(Maslan et al., 2011). MPT was measured by means of three 
tests using the vowel/a/, sustained at the subject’s habitual 
pitch and loudness in a standing position.
• F0high: it is the highest frequency of the subject’s voice. The 
patient was asked to vocalize the vowel “a” with the highest 
tone possible.
• Ilow: it is the lowest intensity of the subject’s voice, measured by 
means of a phonometer (Bruel & Kjaer type 2232) at 30 cm. 
The patient was invited to vocalize the vowel “a” as much softly 
as possible.
For both F0high and Ilow the average of three tests was considered.
VHI: developed and validated by Jacobson in 1997 (Jacobson 
et al., 1997) to assess patients’ perception of the severity of their 
voice, it consists of three domains, including functional, physical, 
and emotional aspects of voice disorders and is administered 
by patients themselves in a five-point Likert-type scale manner 
for each item (from 0, never to 4, always). We used the Italian 
validated version (Schindler et al., 2010).
Voice examination was carried out by a senior ENT specialist 
(RG) experienced in voice diagnostics. He was aware of the timing 
of the study but blind to treatment allocation. The acoustical 
analysis was carried out by means of a personal computer, used to 
operate an MDVP module which acquires, analyzes, and displays 
voice parameters using Visi-Pitch IV hardware system. The 
subject was seated in a quiet room (environmental noise <30 dB, 
monitored through the phonometer Bruel & Kjaer type 2232) 
and instructed to phonate three times, for 3 s, a sustained “a” to a 
microphone (Shure cardioid PGA58-XLR) at a comfortable pitch 
and amplitude. The patient was then requested to repeat three 
times the phonation at the higher possible frequency.
Voice Therapy
Voice therapy was provided in a group format by a senior speech 
language pathologist (SLP) with over 25 years of experience 
FIGURE 1 | Study design.
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in voice rehabilitation (PP), assisted by two graduated SLP 
practitioners (MC, FF). All of them conducted group therapy 
together. Voice rehabilitation consisted of an individually 
tailored combination of indirect and direct techniques. Indirect 
techniques were aimed at increasing the awareness of vocal 
effort, improving vocal hygiene, and eliminating vocal abuse. 
Direct methods included diaphragmatic breathing, coordination 
of breathing with phonation and laryngeal relaxation, with 
attention to reduce the excessive contraction of laryngeal muscles 
and minimize the inappropriate co-contraction of the muscles 
of vocal tract while engaged in phonation. The optimal use of 
resonance and the control of pitch and loudness in reading 
and in spontaneous conversation was finally pursued. Our 
hospital provides intensive voice therapy both to maximize the 
individual’s ability to learn and carryover targets to non-clinical 
environments and to enable patients to return to work as soon as 
possible with an adequate voice (Patel et al., 2011; Fu et al., 2015).
Statistical Analysis
Given the exploratory nature of this pilot trial, no sample size 
analysis was performed. Data are presented as mean (standard 
deviation) or median (range) as appropriate.
Well-balancing of two treatment groups after randomization 
were tested using the Mann–Whitney U test or the Fisher’s exact 
test for continuous and categorical variables, respectively.
Repeated measures analysis of variance (RM-ANOVA) was 
conducted to explore the effect of Qter and Vit A in addition 
to voice rehabilitation on vocal function. Each RM-ANOVA 
model included the raw scores derived from each assessment 
as dependent variable, the study visits (T0, T1, T2, and T3) as 
within-subject factor, and treatment groups (VOC-PLC and 
PLC-VOC) as between-subject factor. The main effect of time 
by group interaction, together with effects size based on Cohen’s 
f-squared, was provided to explore the efficacy of Qter and 
Vit A in improving vocal function. Effect sizes of 0.02, 0.15, 
and 0.35 were termed small, medium, and large, respectively. 
We considered significant a p value < 0.05 in either direction. 
Statistical analyses were performed with the Statistical Package 
for Social Sciences, version 16.0 (IBM SPSS, Chicago, IL, USA).
RESULTS
Participants
From September 2017 to January 2018, a total of 50 patients 
were assessed for eligibility. Two patients declined to participate, 
whereas nine did not meet the inclusion criteria. Thirty-nine 
patients (27 females, 12 males), with a mean age of 50 (15) years, 
were randomized into two counterbalanced group as follows: 
21 were assigned to group A (VOC-PLB) and 18 to group B 
(PLB-VOC). The two treatment groups were similar in terms of 
baseline demographics and clinical characteristics (p ≥0.11 for 
all comparisons). Considering separately for males and females, 
the starting values of F0-high and MPT were not statistically 
different (p ≥ 0.14) (Table 1).
Five patients (four in group A and one in group B) dropped 
out just after completing the first study period (visits T0 and 
T1), thus leading to missing data in the following study periods 
(study visits T2 and T3). Therefore, they were excluded from the 
case-base analysis according to a listwise deletion procedure. 
However, sensitivity analyses were done by replacing missing 
values relative to these five patients according to a “linear trend 
at point” regression method, i.e., the existing series was regressed 
on an index variable scaled 1 to n, and missing data were replaced 
with their predicted values. The study flow diagram is depicted 
in Figure 2.
Main Findings
Mauchly’s test indicated that the sphericity assumption had been 
violated for all study measures [χ2 (2) ranging from 25.6 to 8.1, 
p <0.05]; therefore, the degrees of freedom were corrected by the 
Huynh-Feldt method.
The case-base analysis was performed on 34 patients after 
having excluded the cases with missing data and showed 
significant main effects of time for all measures, with F values 
ranging from 19.5 to 3.2 (p <0.05). The jitter was slightly reduced 
in both groups in the active period only.
Overall, the analysis of main time effect indicates a trend 
toward recovery of vocal function regardless of group assignment, 
likely driven by voice rehabilitation.
We found a significant time by group effect on DSI [F = 3.4 
(2.5, 80.5), p = 0.03], F0-high [F = 4.5 (2.6, 82.9), p = 0.008] 
and Shimmer [F = 3.6 (1.5, 46.9), p = 0.048], indicating a more 
pronounced improvement of vocal function under Qter and 
Vit A treatment, with a small effect size (Table 2). There was 
no significant time by group effect on the other study measures, 
namely MPT, I-low, VHI (Figure 3).
Sensitivity analysis (performed after replacing missing values 
from five patients who dropped out) showed no relevant difference 
with respect to the case-base scenario. We confirmed significant 
main effect of time for all measures (F values ranging from 19.2 
to 3.4, p <0.05) with the exception of jitter [F(2.3, 84.1)  = 1.31, 
p =  0.21]. Time by group effects were nearly significant on DSI 









Sex F:M 27:12 15:6 12:6 0.75
Age, years 50.1 (14.6) 46.9 (13.0) 53.7 (15.7) 0.19
DSI -0.96 (2.41) -1.24 (2.47) -0.63 (2.37) 0.30
MPT, s 12.1 (3.6) 11.4 (3.6) 12.9 (3.4) 0.14
MPT F, s 10.9 (3.1) 12.4 (3.2) 0.28
MPT M, s 13.3 (4.9) 13.0 (3.6) 0.97
F0-high, Hz 248.4 (60.9) 237.5 (51.7) 261.2 (69.5) 0.38
F0- high F, Hz 247.9 (43.4) 291.6 (59.48) 0.14
F0- high M, Hz 183.2 (47.4) 200.5 (37.9) 0.52
I-low, dB 57.4 (5.4) 56.8 (4.4) 58.1 (6.4) 0.59
Jitter, % 1.24 (1.06) 1.37 (1.35) 1.08 (0.55) 0.76
VHI 12.8 (6.8) 10.7 (6.6) 13.2 (6.4) 0.11
F, female; M, male; DSI, Dysphonia Severity Index; MPT, maximum phonation time; 
F0-high, highest phonational frequency; I-low, lowest intensity; VHI, Voice Handicap 
Index.
All values are mean (SD) unless indicated otherwise.
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[F(2.3, 84.5) = 2.8, p = 0.06] and significant on F0-high [F(2.4, 
89.5) = 3.2, p = 0.03] and Shimmer% [F(1.6, 57.2) = 4.33, p = 0.026] 
(Table 2).
No adverse events were reported.
DISCUSSION
The primary endpoint of our study was the change in the 
DSI over the 12-week study period. Although a trend toward 
recovery of vocal function was observed in all the patients, likely 
due to voice rehabilitation, greater and significant changes on 
DSI (p = 0.03) were found in the experimental group, showing 
a substantial effect of Qter and Vit A on vocal improvement 
of patients undergoing voice therapy. MTD is characterized 
by the hypercontraction of the laryngeal musculature which 
reduces the vocal efficiency thus forcing the patient into an 
increased muscular effort, with establishment of a vicious 
circle. We can assume that the increased levels of Qter may 
have improved the bioenergetic functions of the respiratory 
and phonatory system, allowing a better voice recovery in the 
experimental groups.
With regard to the secondary outcomes, we found a 
significant increase of the F0-high (p = 0.008). This parameter is 
not enough, in itself, to show an improvement of vocal quality, 
but its increase confirms the improved vibration of the vocal 
FIGURE 2 | Study flow diagram.
TABLE 2 | Summary of the main study findings reporting the effect of time by 
group interaction (estimated by RM-ANOVAs) in the case-base analysis (n = 35) 





DSI F[2.5, 80.5] 3.39 F[2.3, 84.5] 2.79
P 0.03 p 0.06
ES 0.08 ES 0.04
MPT, s F[2.8, 90.4] 0.71 F[3.0, 95.8] 0.50
P 0.54 p 0.66
ES 0.02 ES 0.01
F0-high, Hz F[2.6, 82.9] 4.49 F[2.4, 89.5] 3.21
P 0.008 p 0.03
ES 0.12 ES 0.08
I-low, dB F[2.5, 81.3] 0.87 F[2.4, 88.2] 0.55
P 0.44 p 0.61
ES 0.02 ES 0.01
Jitter, % F[2.4, 75.3] 1.65 F[2.3, 84.1] 1.68
P 0.19 P 0.19
ES 0.05 ES 0.05
VHI F[2.3, 69.9] 1.39 F[2.1, 75.4] 1.13
P 0.25 P 0.33
ES 0.04 ES 0.03
Shimmer,% F[1.5, 46.9] 3.58 F[1.6, 57.2] 4.33
P 0.048 P 0.026
ES 0.07 ES 0.08
DSI, Dsyphonia Severity Index; MPT, maximum phonation time; F0-high, highest 
phonational frequency; I-low, lowest intensity; VHI, Voice Handicap Index.
Bold values denote statistical significance.
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folds at the high frequencies. This could be explained by the 
beneficial effects of Vit A in restoring the normal texture of the 
laryngeal mucosa. Vocal folds are layered structures, consisting 
of an inner muscular layer (the thyroarytenoid muscle), a soft 
tissue layer of the lamina propria, and an outmost epithelium 
layer. When using the “chest voice” at the lower frequencies, all 
the structures of  the vocal fold are involved in the vibration, 
whereas the “falsetto” voice is mainly due to the uncoupled 
vibration of the epithelium layer only. So, the high-frequency 
vibration requires the perfect efficiency of the biomechanical 
properties of the epithelium and of the extracellular matrix, to 
which Vit A contributes. The highest frequency is among the 
chosen parameters of DSI since every alteration of the vocal 
mucosa hampers the higher vibratory rates, which is reflected by 
a decreased F0 (15). The jitter% values showed also a reduction 
in the active periods for both groups, although failed to reach 
the statistical significance. This may be due to the small sample 
size. It should be noted that the Shimmer% values, one of our 
exploratory endpoints, showed a significant reduction in the 
active groups (p = 0.048). The improvement of both MPT and 
VHI did not reach the statistical significance. In our clinical 
experience however, the increased awareness of the vocal effort 
after voice therapy usually results in the reluctance of patients to 
maintain a sustained phonation for a long time and in judging 
more severely the consequences of their dysphonia. This could 
explain such results, an exploration of data from larger series 
of patients who underwent voice rehabilitation in the future 
will shed more light on this observation. Furthermore, if the 
short time elapsed from the baseline (3 months) has been 
enough to allow a first improvement of voice quality following 
FIGURE 3 | Mean values of study assessments collected over the 12-week follow-up period (case-base analysis, n = 34).
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rehabilitation, we can assume that patients enduring over time 
in the correct vocal behavior will achieve even better phoniatric 
results. The intensive voice treatment can justify the generalized 
improvement in vocal function but does not affect results, due 
to the methodology of the study, randomized and conducted in 
a three-period cross-over.
Unlike previous reports, this is the first double-blind, 
randomized, controlled, three-period cross-over study about 
the efficacy of the adjuvant therapy on voice recovery. Most 
likely, a larger sample size would have allowed to achieve a 
more profound statistical significance, particularly on data 
from sensitivity analysis. We encountered great difficulties 
both in recruiting patients willing to undergo a prolonged voice 
therapy during working hours and in selecting patients who met 
the inclusion criteria, particularly without laryngo-pharyngeal 
reflux signs or epithelial thickening of the vocal folds. Most 
patients did not agree to undergo plasma analysis, which would 
have resulted in stronger data. Another limitation of our study 
could be that we have not analyzed data from laryngoscopy. 
This choice was motivated by the difficult interpretation of 
their clinical value—signs of vocal hyperfunction were found 
also in asymptomatic subjects (Morrison et al., 1983; Belafsky 
et al., 2002)—and by the greater complexity of statistical 
processing due to their inclusion, without the addition of 
objective information. For the same reason we did not use the 
most widely accepted perceptual judgment protocol, namely 
the GIRBAS, which is affected by several sources of variability, 
such as the professional experience of the examiner and the type 
of examined sample (Dejonckere et al., 1993). On the contrary, 
the aerodynamic measures are objective, and they would have 
been useful in evaluating the increased phonatory flow in 
patients suffering from MTD. However, they are invasive, not 
easy to perform, and may cause discomfort to the patients. So, 
the only aerodynamic measure we used was the MPT, which 
is routinely employed in the assessment of voice functionality 
and is included in the DSI. Ultimately, we have chosen the DSI 
as a reference value to assess the voice to facilitate statistical 
data processing, because it allows the use a single parameter to 
define the quality of a multidimensional function, as the voice 
is. DSI indeed includes voice range profiles, aerodynamic, and 
acoustic measurement.
In conclusion from our double-blind randomized, three-
period cross-over pilot study, a combination of CoQ10 and 
vitamin A was confirmed to be a useful adjuvant therapy in 
voice rehabilitation.
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